Literature DB >> 2692940

The role of therapeutic drug monitoring in children.

L O Boréus1.   

Abstract

Routine use of therapeutic drug monitoring in children is helpful in individualizing the dosage during long term treatment (e.g. theophylline and antiepileptic drugs) and in checking against toxic accumulation of drug in neonates (e.g. digoxin, theophylline/caffeine and aminoglycoside antibiotics). In individual patients, measurements of drug concentrations in plasma may be the only way to elucidate clinically unexpected drug effects or to handle interaction phenomena. Knowledge of the pharmacokinetic and pharmacodynamic changes during development is a prerequisite for a correct interpretation of the concentration values. Unfortunately, the quantitative relation between kinetics and clinical effect is still relatively poorly known for many drugs in the paediatric age groups. Apart from the pharmacokinetic informative value, therapeutic drug monitoring also has some merit as an aid to the physician in explaining to the patient and the parents why the drug should be taken as instructed. This may improve compliance.

Entities:  

Mesh:

Year:  1989        PMID: 2692940     DOI: 10.2165/00003088-198900171-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  8 in total

Review 1.  Therapeutic drug monitoring in childhood.

Authors:  N Buchanan
Journal:  Aust Paediatr J       Date:  1986-02

Review 2.  Cost-effectiveness of therapeutic drug monitoring.

Authors:  S Vozeh
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

3.  Total body digoxin clearance and steady-state concentrations in low birth weight infants.

Authors:  R L Collins-Nakai; P K Ng; M A Beaudry; R Ocejo-Moreno; D Schiff; G R Van Petten
Journal:  Dev Pharmacol Ther       Date:  1982

Review 4.  Drug level monitoring in paediatric practice.

Authors:  G W Rylance; T A Moreland
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

5.  Pharmacokinetics and dosagae of digoxin in neonates and infants.

Authors:  L Nyberg; G Wettrell
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

6.  Absolute bioavailability of oral theophylline.

Authors:  L Hendeles; M Weinberger; L Bighley
Journal:  Am J Hosp Pharm       Date:  1977-05

7.  Kinetic model for gentamicin dosing with the use of individual patient parameters.

Authors:  R J Sawchuk; D E Zaske; R J Cipolle; W A Wargin; R G Strate
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

8.  Maintenance digoxin dosage and steady-state plasma concentration in infants and children.

Authors:  A R Hastreiter; R L van der Horst; C Voda; E Chow-Tung
Journal:  J Pediatr       Date:  1985-07       Impact factor: 4.406

  8 in total
  4 in total

1.  Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria.

Authors:  J S Sidhu; M Ashton; N V Huong; T N Hai; M O Karlsson; N D Sy; E N Jonsson; L D Cong
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 2.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.